Objectives to evaluate laboratory and instrumental indicators, associated with decreased left ventricle ejection fraction in patients with heart failure of ischemic etiology. Material and methods. The observational study included 71 patient with coronary heart disease and chronic heart failure (CHF). All patients underwent the testing on the following parameters: uric acid concentration, C-reactive protein (hs-CRP), NT-proBNP, ST2 and cystatin C tests, glomerular filtration rate. Instrumental examination included transthoracic echocardiography and 6-minute walk test. Results. The study revealed several indicators, associated with decreased left ventricle ejection fraction less than 50% in patients with CHF: NT-proBNP level 822.2 pg/ml, ST2 38.61 ng/l, uric acid 419.9 mmol/l, hs-CRP 2.54 mg/l, end diastolic volume index 73.68 ml/m2, left ventricular mass index 127 g/m2, left ventricular contractility index 1.75, pulmonary artery pressure 29 mm Hg. and vena cava inferior diameter 20 mm.

Objectives to determine the clinical and instrumental relationships and prognostic value of sST2 in chronic heart failure with reduced and mid-range ejection fraction of ischemic etiology. Material and methods. The study included examination of 64 patients with heart failure with left ventricular ejection fraction 50% and myocardial infarction in medical history; mean age 55.7 8.7 years. Results. Higher concentrations sST2 was determined with an increased end-diastolic volume, left ventricular aneurysm, left main coronary artery stenosis, glomerular filtration rate 90 ml/min/1.73 m2 (p 0.05 for all ). The study confirmed a high predictive significance of increased levels sST2 (p = 0.001); the area under the curve was 0.772; the odds ratio for an adverse outcome with sST2 35 ng/ml was 3.93. Conclusion. sST2 is a predictor of adverse outcome during the first year of follow-up in patients with heart failure with reduced and mid-range ejection fraction of ischemic etiology.

Aim. This study aims to investigate the effect of senile asthenia syndrome (SAS) on the cardiovascular mortality risk within 12 months in patients over 70 years of age with myocardial infarction.Material and methods. We performed a retrospective study of 92 patients over 70 years of age with myocardial infarction, who agreed to participate. To detect senile asthenia syndrome, we used the questionnaire "Age is not a hindrance". We estimated the anamnestic data, and also laboratory and instrumental parameters. The follow-up period was 12 months. As an end-point, the onset of an adverse event — cardiovascular death was chosen. Statistical nonparametric methods, ROC analysis, Kaplan-Meier survival analysis (p<0,05) were used.Results. In 12 months, 19 patients (20,65%) met the end-point. The median (25%; 75%-quartile) of the numbers of points according to the questionnaire "Age is not a hindrance" was significantly higher in the group of dead patients than in the group without adverse outcomes — 4 (3; 5) and 2 (1; 4) points (p<0,001). When gaining 3 or more points according to the questionnaire "Age is not a hindrance", risk ratio of cardiovascular death within 12 months was 1,72; 95% confidence interval: 1,28-2,30 (p=0,001). In conduction of ROC analysis to predict adverse outcome when gaining 3 or more points according to the questionnaire "Age is not a hindrance", the area under the curve (AUC) was 0,78 (p<0,001), sensitivity — 89%, specificity — 60%.Conclusion. The risk of cardiovascular death within 12 months after myocardial infarction in patients over 70 years of age with SAS increases by 72%. The inclusion of the results from the questionnaire "Age is not a hindrance" into prognostic models, and the SAS estimation in this cohort of patients will improve the risk stratification.